Literature DB >> 9190969

Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival.

G A Johnson1, R Mannel, M Khalifa, J L Walker, M Wren, K W Min, D M Benbrook.   

Abstract

OBJECTIVE: To evaluate the level of epidermal growth factor receptor (EGF-R) expression in vulvar malignancies and to determine if a correlation exists between EGF-R levels and metastasis or patient survival.
METHODS: All patients with a diagnosis of invasive squamous cell carcinoma of the vulva who were treated at our institution with a primary radical vulvectomy and inguinal lymph node dissection from 1983 to 1993 were eligible for the study. Sixty-one patients with available tissue blocks of benign vulvar epithelium, the primary malignant vulvar lesion, and groin node metastasis (when positive) were included in the study. Semiquantitative EGF-R expression was determined in a blinded fashion utilizing immunohistochemical staining of appropriate tissue samples. Survival was calculated utilizing Kaplan-Meier life table analysis based upon disease-free survival.
RESULTS: A significant increase (P < 0.001) in mean EGF-R levels was demonstrated in the primary tumor (67%) versus benign vulvar epithelium (31%). In the 14 patients with lymph node metastasis, the mean EGF-R level in the primary tumor was 65% versus 88% in the metastatic lesion (P < 0.001). The likelihood of lymph node metastasis was elevated in those patients with a benign tissue EGF-R level > or =40% (P < 0.03) and in those patients with a primary tumor EGF-R level > or =90% (P < 0.025). Life table analysis revealed a cumulative disease-free survival of 45% for all patients. Disease-free survival in those patients with EGF-R levels > or =90% in the primary tumor was 25%, contrasting with a disease-free survival of 54% in those patients with EGF-R levels <90% (P < 0.05).
CONCLUSIONS: There is a progressive increase in EGF-R expression from benign vulvar epithelium to primary malignant tissue to metastatic lesions within the same patient. Increased expression of EGF-R in the primary vulvar malignancy is significantly associated with lymph node metastasis and decreased patient survival. Increased expression of EGF-R in histologically benign vulvar epithelium has a significant association with lymph node metastasis and may predict decreased patient survival.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9190969     DOI: 10.1006/gyno.1997.4660

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

1.  Long term response to erlotinib in a patient with recurrent vulvar carcinoma: Case report and review of literature.

Authors:  Hanane Inrhaoun; Ibrahim Elghissassi; Maya Gutierrez; Etienne Brain; Hassan Errihani
Journal:  Gynecol Oncol Case Rep       Date:  2012-07-27

2.  Tumor proteomics by multivariate analysis on individual pathway data for characterization of vulvar cancer phenotypes.

Authors:  Annsofi Sandberg; Gunnel Lindell; Brita Nordström Källström; Rui Mamede Branca; Kristina Gemzell Danielsson; Mats Dahlberg; Barbro Larson; Jenny Forshed; Janne Lehtiö
Journal:  Mol Cell Proteomics       Date:  2012-04-12       Impact factor: 5.911

Review 3.  Theranostic applications of antibodies in oncology.

Authors:  Emmy D G Fleuren; Yvonne M H Versleijen-Jonkers; Sandra Heskamp; Carla M L van Herpen; Wim J G Oyen; Winette T A van der Graaf; Otto C Boerman
Journal:  Mol Oncol       Date:  2014-03-21       Impact factor: 6.603

Review 4.  Molecular targeted therapy in gynaecologic malignancies: primer for radiologists.

Authors:  Chong Hyun Suh; Sree H Tirumani; Abhishek Keraliya; Kyung Won Kim; Nikhil H Ramaiya; Atul B Shinagare
Journal:  Br J Radiol       Date:  2016-07-12       Impact factor: 3.039

Review 5.  Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies.

Authors:  Simona Maria Fragomeni; Frediano Inzani; Anna Fagotti; Luigi Della Corte; Stefano Gentileschi; Luca Tagliaferri; Gian Franco Zannoni; Giovanni Scambia; Giorgia Garganese
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-25       Impact factor: 4.553

Review 6.  Chemotherapy of vulvar cancer: a review.

Authors:  Gunter Deppe; Ismail Mert; Jimmy Belotte; Ira S Winer
Journal:  Wien Klin Wochenschr       Date:  2013-03-22       Impact factor: 1.704

Review 7.  Molecular events in the pathogenesis of vulvar squamous cell carcinoma.

Authors:  Deyin Xing; Oluwole Fadare
Journal:  Semin Diagn Pathol       Date:  2020-09-25       Impact factor: 3.464

8.  Hemoglobin level predicts outcome for vulvar cancer patients independent of GLUT-1 and CA-IX expression in tumor tissue.

Authors:  Hedwig P van de Nieuwenhof; Joanne A de Hullu; Johannes H A M Kaanders; Johan Bulten; Leon F A G Massuger; Léon C L T van Kempen
Journal:  Virchows Arch       Date:  2010-10-02       Impact factor: 4.064

9.  Use of Cetuximab in Combination with Cisplatin and Adjuvant Pelvic Radiation for Stage IIIB Vulvar Carcinoma.

Authors:  Jennifer Bergstrom; Michael Bidus; Edward Miles; Jay Allard
Journal:  Case Rep Obstet Gynecol       Date:  2015-07-29

Review 10.  Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists.

Authors:  Ailbhe C O'Neill; Jyothi P Jagannathan; Nikhil H Ramaiya
Journal:  Korean J Radiol       Date:  2017-01-05       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.